- Investing Ideas
- U.S. Pharmaceuticals & Biotech High ROE Growth Engines
U.S. Pharmaceuticals & Biotech High ROE Growth Engines
Results
15
15 companies
Incyte
Market Cap: US$25.9b
A biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan.
INCY
US$127.81
7D
3.5%
1Y
50.8%
Exelixis
Market Cap: US$13.4b
An oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States.
EXEL
US$54.08
7D
3.4%
1Y
42.7%
ACADIA Pharmaceuticals
Market Cap: US$5.1b
A biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America.
ACAD
US$29.50
7D
1.7%
1Y
16.5%
CareDx
Market Cap: US$2.5b
Provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally.
CDNA
US$48.61
7D
4.8%
1Y
281.3%
ADMA Biologics
Market Cap: US$2.2b
A biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.
ADMA
US$9.84
7D
5.4%
1Y
-42.2%
Innoviva
Market Cap: US$1.5b
Operates as a biopharmaceutical company in the United States and internationally.
INVA
US$21.07
7D
0.5%
1Y
6.6%
MeiraGTx Holdings
Market Cap: US$1.4b
A clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases.
MGTX
US$14.34
7D
4.1%
1Y
89.2%
Zevra Therapeutics
Market Cap: US$704.9m
A commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States.
ZVRA
US$11.87
7D
2.9%
1Y
26.8%
CorMedix
Market Cap: US$639.1m
A biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States.
CRMD
US$8.20
7D
6.9%
1Y
-40.3%
Q32 Bio
Market Cap: US$475.4m
A clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction.
QTTB
US$15.97
7D
0.1%
1Y
710.7%
Compugen
Market Cap: US$247.7m
A clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe.
CGEN
US$2.62
7D
11.3%
1Y
82.9%
Protalix BioTherapeutics
Market Cap: US$191.8m
A biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system.
PLX
US$2.38
7D
3.9%
1Y
48.8%
Vaxart
Market Cap: US$125.1m
A clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform.
VXRT
US$0.52
7D
4.3%
1Y
45.8%
Rallybio
Market Cap: US$89.4m
A clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases.
RLYB
US$16.83
7D
-1.0%
1Y
261.6%
Actinium Pharmaceuticals
Market Cap: US$34.6m
Develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies.
ATNM
US$1.10
7D
4.8%
1Y
-38.5%